Publisher Correction Issued for Multiple Myeloma Molecular Predictors Study
Nature Medicine updates abstract text regarding quadruplet therapy research for newly diagnosed myeloma.
1Correction to Research Abstract
Nature Medicine has issued a formal publisher correction for an article originally published on 19 October 2026. The study focuses on molecular predictors of minimal residual disease in patients diagnosed with multiple myeloma. The correction specifically addresses incomplete text found within the seventh and eighth sentences of the original abstract section.
2Scope of the Amendment
The identified errors in the abstract have now been rectified in both the HTML and PDF versions of the article. This update ensures that the scientific record accurately reflects the findings regarding quadruplet therapy. Researchers and clinicians accessing the digital publication will now see the corrected text as intended by the authors.
3Supervisory Authorship Clarification
The correction also serves to formally clarify the supervisory roles of the research team. Stéphane Minvielle and Eric Letouzé are now explicitly identified as the joint supervisors of this work. This attribution reflects the collaborative effort between various institutions, including Nantes Université, INSERM, CNRS, and the Université d’Angers in France.
4Institutional Research Collaboration
The study involves a broad network of medical and research institutions across France and the United States. Key contributors include the Centre Hospitalier Universitaire de Nantes, the Sylvester Comprehensive Cancer Center in Miami, and the Dana Farber Cancer Institute in Boston. These partnerships facilitate large-scale clinical data analysis for oncology research.
5Clinical Context of Myeloma
Multiple myeloma is a complex hematological malignancy requiring precise therapeutic strategies. The research focuses on quadruplet therapy, a treatment regimen intended to improve patient outcomes. Identifying molecular predictors for minimal residual disease is critical for assessing treatment efficacy and long-term prognosis in patients who have been newly diagnosed with this condition.
6Data and Statistical Rigor
The research incorporates expertise from departments of biostatistics and data science, including contributions from the Harvard T.H. Chan School of Public Health. Such interdisciplinary involvement is essential for interpreting molecular data accurately. The study aims to refine how clinicians evaluate the presence of residual cancer cells following intensive therapeutic interventions.
7Licensing and Access Terms
The article is published under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. This allows for non-commercial sharing and distribution, provided that appropriate credit is given to the original authors. Users must obtain direct permission from the copyright holder if they intend to adapt the material or exceed the defined permitted use.
8Significance of Scientific Accuracy
Maintaining the integrity of published medical research is vital for the oncology community. By correcting the abstract, the authors ensure that the scientific community can rely on the provided data for future clinical applications. This transparency supports the ongoing effort to improve treatment protocols for patients undergoing complex quadruplet therapy regimens.